Gastroenterology
Gastroenterology
Audio Summaries
Every issue of Gastroenterology moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from Gastroenterology.
Serrated neoplasia of the colorectum: updates on pathology and clinical management.
Nov 17, 2026
This comprehensive review examines serrated neoplasia, a colorectal carcinogenesis pathway responsible for up to 30% of colorectal cancers and a disproportionate share of post-colonoscopy CRC. The authors ask how to improve the recognition, histologic classification (using the 6th edition WHO criteria), endoscopic resection, and surveillance of serrated polyps, with a focus on the sessile serrated lesion detection rate as a quality benchmark. They synthesize molecular pathways, risk factors, and current international guidelines to help gastroenterologists, pathologists, and primary care providers reduce the CRC burden from this pathway.
Depletion of Endogenous IL-18 Suppresses Pancreatic Cancer Progression, Reprograms the Tumor Microenvironment, and Enhances KRAS Inhibitor Efficacy.
Nov 13, 2026
Pancreatic cancer is highly inflammatory and immunosuppressive, and IL-18 is elevated in this disease and linked to poor survival, but its functional role was unclear. Using genetically engineered mice with spontaneous PDAC, the authors show that depleting IL-18 slows tumor progression and prolongs survival, and that IL-18 promotes cancer cell survival by inducing STAT1-dependent CD47 expression that blocks macrophage phagocytosis. IL-18 loss also reprograms macrophages toward an antigen-presenting, phagocytic state and enhances clearance of KRAS inhibitor-treated cells, suggesting that targeting IL-18 could improve KRAS inhibitor therapy.
TASTY AND HEALTHY DIET REDUCES FECAL CALPROTECTIN IN HIGH-RISK FIRST-DEGREE RELATIVES OF PATIENTS WITH CROHN'S DISEASE: PIONIR RANDOMIZED CROSSOVER TRIAL.
Oct 26, 2026
The PIONIR randomized crossover trial asked whether the Tasty&Healthy (T&H) diet can reduce fecal calprotectin, a marker of intestinal inflammation, in healthy first-degree relatives of Crohn's disease patients who have persistently elevated calprotectin but no diagnostic evidence of disease. In this 29-participant study, fecal calprotectin was lower after 8 weeks on T&H than on habitual diet (median 64 vs. 112 μg/g; P=.022), and a ≥50% reduction was far more common with T&H (71% vs. 27%). The authors conclude that low-grade intestinal inflammation in this high-risk group is modifiable through diet, supporting larger long-term dietary prevention trials.
AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis.
Oct 23, 2026
This AGA/AASLD guideline sets evidence-based recommendations for adults with primary biliary cholangitis, addressing how to diagnose antimitochondrial antibody-negative disease, assess UDCA response, risk-stratify patients, treat inadequate responders, manage pruritus, and prevent post-transplant recurrence. The panel issued six recommendations, including PBC-specific antinuclear antibody testing in suspected AMA-negative cases, UDCA as first-line therapy, liver stiffness measurement for prognosis, PPAR agonists for UDCA inadequate responders or intolerant patients, linerixibat for moderate-to-severe pruritus, and UDCA prophylaxis after transplantation. Certainty of evidence ranged from moderate to very low, and the guideline emphasizes early diagnosis and risk-based treatment escalation to improve outcomes.
Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer.
Oct 22, 2026
The authors investigate the metabolic adaptations that occur in pancreatic ductal adenocarcinoma (PDAC) cells following acquired resistance to gemcitabine, aiming to identify potential therapeutic vulnerabilities. They find that gemcitabine-resistant cells exhibit a dependency on the mevalonate biosynthesis pathway, making them sensitive to statin treatment, and suggest that HMGCR expression could serve as a biomarker for predicting treatment response in PDAC patients.
Microbiota-Taurine Pathway Links Dietary Fiber to Mucosal Healing.
Oct 22, 2026
The authors investigate whether dietary fiber, specifically alginate, promotes mucosal healing in colitis through microbiota-dependent mechanisms. Their study demonstrates that alginate enhances recovery from DSS-induced colitis by enriching taurine-releasing bacteria and increasing intestinal taurine levels, which are crucial for epithelial repair. Although a clinical trial did not meet its primary endpoint, the observed biological changes suggest potential for alginate as a microbiota-targeted intervention in ulcerative colitis.
Myofibroblast Derived Transglutaminase 2 Activity is Upregulated in Stricturing Crohn's Disease and its Inhibition Exerts Anti-Fibrotic Properties.
Oct 13, 2026
Intestinal fibrosis in Crohn's disease is a major clinical problem, and this study asks whether transglutaminase 2 (TG2), an enzyme that can act directly on the extracellular matrix, drives fibrosis independently of inflammation. The authors found that TG activity was elevated in stricturing Crohn's disease, that myofibroblasts were the main TG2 source, and that TG2 inhibition or inducible knockout of TGM2 reduced matrix accumulation and experimental fibrosis without changing inflammation. These results suggest TG2 may contribute to inflammation-independent progression of intestinal fibrosis.
HtpG-High-Expressing Escherichia coli Promotes Fibrosis in Chronic Pancreatitis.
Oct 13, 2026
Chronic pancreatitis is a progressive fibroinflammatory disease with no cure, and this study asked whether specific gut bacteria causally drive its pathogenesis. The authors found that HtpG-high-expressing *E. coli* (HHEC) is enriched in patients, and that its HtpG protein promotes fibrosis by upregulating PRMT5 in pancreatic macrophages, which methylates and stabilizes KLF4 to drive M2 polarization. Blocking HHEC colonization or PRMT5 alleviated disease in mice, and treatment with *Akkermansia muciniphila* suppressed HHEC and ameliorated pancreatitis, suggesting microbiota-targeted therapy as a potential strategy.
Gut Inflammation Favors Adverse Food Reactions by Disrupting the Microbial Metabolism of Food Triggers.
Oct 7, 2026
Adverse food reactions are common in inflammatory bowel disease (IBD), but their causes are unclear. This study asks whether intestinal inflammation disrupts microbial metabolism of food, thereby promoting food sensitization. In mice, inflammation depleted food-digesting gut bacteria, which led to mast cell-driven sensitization and visceral pain on food re-exposure; restoring those bacteria or stabilizing mast cells reduced these responses, and IBD patients in remission showed similar microbial depletion alongside frequent self-reported food intolerances.
Faecalibacterium prausnitzii EXL01 Strain for the prevention of multiple-recurrent Clostridioides difficile Infection
Sep 17, 2026
The authors aimed to evaluate the efficacy of the Faecalibacterium prausnitzii EXL01 strain in preventing recurrent Clostridioides difficile infection (rCDI) by restoring microbiome functions. In a murine model and a phase I clinical trial with adults who had multiple CDI episodes, EXL01 demonstrated safety and a high rate of recurrence-free patients, suggesting its potential as a precision microbiome therapeutic. The study highlights the importance of targeting microbiome function rather than solely focusing on taxonomic diversity in treating rCDI.
